Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

  • ID: 3946434
  • Drug Pipelines
  • 420 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Axelar AB
  • Coherus BioSciences, Inc.
  • ERC Belgium SA
  • Kadmon Corporation, LLC
  • Pfizer Inc.
  • MORE
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline landscape.

Recurrent glioblastoma multiforme (GBM) is one of the most aggressive primary brain tumors. Recurrent tumors develop near the original site or at more distant satellite lesions within the brain. Symptoms include headache, nausea, vomiting, vision problem, seizures and intracranial hemorrhage. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 46, 11 and 7 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 5 molecules, respectively for Recurrent Glioblastoma Multiforme (GBM).

Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Recurrent Glioblastoma Multiforme (GBM) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Recurrent Glioblastoma Multiforme (GBM) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Axelar AB
  • Coherus BioSciences, Inc.
  • ERC Belgium SA
  • Kadmon Corporation, LLC
  • Pfizer Inc.
  • MORE
Introduction

Recurrent Glioblastoma Multiforme (GBM) Overview

Therapeutics Development

Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies

Recurrent Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes

Recurrent Glioblastoma Multiforme (GBM) - Pipeline Products Glance

Recurrent Glioblastoma Multiforme (GBM) - Products under Development by Companies

Recurrent Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes

Recurrent Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development

Recurrent Glioblastoma Multiforme (GBM) - Therapeutics Assessment

Drug Profiles

Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects

Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products

Recurrent Glioblastoma Multiforme (GBM) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2016

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Development by Companies, H2 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Development by Companies, H2 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by AngioChem Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Arog Pharmaceuticals, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by BeiGene, Ltd., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Boston Biomedical, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Bristol-Myers Squibb Company, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cavion LLC, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Coherus BioSciences, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Cortice Biosciences, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eisai Co., Ltd., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ERC Belgium SA, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Genzyme Corporation, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline Plc, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by GW Pharmaceuticals Plc, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Inspyr Therapeutics Inc, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Kadmon Corporation, LLC, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Medicenna Therapeutics, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Merck & Co., Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Neonc Technologies Inc, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Oryx GmbH & Co. KG, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by StemGen S.p.A, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Tocagen Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals Inc, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vascular Biogenics Ltd., H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Vaximm AG, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Pipeline by Virttu Biologics Limited, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects, H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H2 2016

Recurrent Glioblastoma Multiforme (GBM) - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H2 2016

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Top 10 Routes of Administration, H2 2016

Number of Products by Stage and Top 10 Routes of Administration, H2 2016

Number of Products by Top 10 Molecule Types, H2 2016

Number of Products by Stage and Top 10 Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc
Agenus, Inc.
Amgen Inc.
AngioChem Inc.
Apogenix GmbH
Arog Pharmaceuticals, Inc.
Axelar AB
BeiGene, Ltd.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Cavion LLC
Coherus BioSciences, Inc.
Cortice Biosciences, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EnGeneIC Ltd
ERC Belgium SA
Genzyme Corporation
GlaxoSmithKline Plc
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics, Ltd.
Inspyr Therapeutics Inc
Kadmon Corporation, LLC
Karyopharm Therapeutics, Inc.
Les Laboratoires Servier SAS
Medicenna Therapeutics, Inc.
Merck & Co., Inc.
Neonc Technologies Inc
Novartis AG
Ono Pharmaceutical Co., Ltd.
Oryx GmbH & Co. KG
Pfizer Inc.
StemGen S.p.A
Stemline Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
Tocagen Inc.
TRACON Pharmaceuticals Inc
Upsher-Smith Laboratories, Inc.
Vascular Biogenics Ltd.
Vaximm AG
Virttu Biologics Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll